4D Molecular Therapeutics Grants 21,800 RSUs to 1 New Employee

Q: What critical role did 4DMT just fill with a 21,800-RSU bonus as it races toward 2027 Phase 3 gene therapy readouts?

4DMT has not publicly identified the exact job title of the employee who received the 21,800-RSU inducement grant. What the company disclosed is narrow: one newly hired non-executive employee was awarded 21,800 RSUs on Nov. 10 under its 2025 Employment Inducement Award Plan to join the company. The filing did not name the person or specify the role. The broader hiring pattern suggests the position is likely tied to late-stage execution as 4DMT pushes toward 2027 Phase 3 readouts for 4D-150 in wet AMD and diabetic macular edema. Recent openings and recruiting activity show emphasis on functions critical to that push, including clinical operations, regulatory affairs, talent acquisition, and R&D IT systems supporting GxP, data integrity, and inspection readiness. That matters because 4DMT is moving from development into a more complex pre-commercial phase. The company has said 4FRONT-1 topline wet AMD data are expected in Q2 2027 and 4FRONT-2 in H2 2027, while its 4SIGHT Phase 3 DME trial has begun enrolling. It is also building infrastructure for a potential first BLA and eventual launch. So the best factual answer is that the “critical role” was a newly filled non-executive position, but 4DMT did not disclose which one. The available evidence points to ongoing hiring in trial execution, regulatory, and R&D-support roles needed to deliver those 2027 gene therapy milestones.

2 articles · Updated · Yahoo Canada Finance · Nov 13

November 10 grants gave one new non-executive hire 21,800 restricted stock units, 4D Molecular Therapeutics said Friday.
The award was issued under the company's amended 2025 Employment Inducement Award Plan and structured to induce the employee to join 4DMT under Nasdaq Rule 5635(c)(4).
4DMT, a late-stage biotech based in Emeryville, California, is advancing lead candidate 4D-150 in Phase 3 for wet age-related macular degeneration and diabetic macular edema.
The company also highlighted 4D-710, a cystic fibrosis genetic medicine candidate, while noting all of its programs remain in clinical or preclinical development and are not yet approved.